数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
曹伟 创始人、董事会主席兼首席执行官 62 未披露 9209.00 2021-01-07
Guotong Xu 董事 63 未披露 未持股 2021-01-07
Wendy Hayes 董事 50 未披露 未持股 2021-01-07
David Guowei Wang 董事 59 未披露 未持股 2021-01-07
Lili Shen 董事 42 未披露 未持股 2021-01-07

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
曹伟 创始人、董事会主席兼首席执行官 62 未披露 9209.00 2021-01-07
Martina Sersch 首席医疗官 48 未披露 未持股 2021-01-07
Yili Kevin Xie 首席财务官 50 未披露 未持股 2021-01-07

董事简历

中英对照 |  中文 |  英文
曹伟

曹伟,曹先生自2013年2月起担任我们总裁兼首席运营官,直至2013年9月29日获委任为我们首席执行官。曹先生自2013年2月起担任我司董事会董事。在此之前,2010年8月至2013年2月,曹博士担任Cellular Biomedicine Group Ltd.(我们的前身公司)总裁、COO兼董事。2006年8月至2010年7月,曹博士担任基因分析行业公司Affymetrix中国公司总经理兼董事长。曹博士在科研、产品开发和创业方面拥有30多年的专业经验。曾任拜耳诊断亚太区(现西门子)技术经理、Genomultix有限公司总经理、无锡新区医院院长。曹博士在哈佛医学院和斯坦福大学医学中心的免疫药理学领域有丰富的研究经验。曹博士拥有复旦大学医学院医学学士学位,弗吉尼亚州里士满弗吉尼亚医学院药理学博士学位。他是基因分析和干细胞技术领域,特别是脂肪来源干细胞制备及其疾病治疗应用领域26项专利中命名的发明人。


Wei Cao has served as our Chairman of the Board and Chief Executive Officer since May 2017. Prior to founding our company, Dr. Cao co-founded Cellular Biomedicine Group, Inc. Nasdaq: CBMG, a Nasdaq-listed company engaging in developing proprietary cell therapies for the treatment of cancer and degenerative diseases, and served several positions at CBMG, such as chief operating officer, chief executive officer and director, from August 2010 to January 2016. Dr. Cao holds a Bachelor’s degree in Medicine from Fudan University Medical College, Shanghai China, and a Ph.D. in Pharmacology from Medical College of Virginia, Richmond Virginia. Dr. Cao holds over 80 issued patents and applications for advanced cell therapies.
曹伟,曹先生自2013年2月起担任我们总裁兼首席运营官,直至2013年9月29日获委任为我们首席执行官。曹先生自2013年2月起担任我司董事会董事。在此之前,2010年8月至2013年2月,曹博士担任Cellular Biomedicine Group Ltd.(我们的前身公司)总裁、COO兼董事。2006年8月至2010年7月,曹博士担任基因分析行业公司Affymetrix中国公司总经理兼董事长。曹博士在科研、产品开发和创业方面拥有30多年的专业经验。曾任拜耳诊断亚太区(现西门子)技术经理、Genomultix有限公司总经理、无锡新区医院院长。曹博士在哈佛医学院和斯坦福大学医学中心的免疫药理学领域有丰富的研究经验。曹博士拥有复旦大学医学院医学学士学位,弗吉尼亚州里士满弗吉尼亚医学院药理学博士学位。他是基因分析和干细胞技术领域,特别是脂肪来源干细胞制备及其疾病治疗应用领域26项专利中命名的发明人。
Wei Cao has served as our Chairman of the Board and Chief Executive Officer since May 2017. Prior to founding our company, Dr. Cao co-founded Cellular Biomedicine Group, Inc. Nasdaq: CBMG, a Nasdaq-listed company engaging in developing proprietary cell therapies for the treatment of cancer and degenerative diseases, and served several positions at CBMG, such as chief operating officer, chief executive officer and director, from August 2010 to January 2016. Dr. Cao holds a Bachelor’s degree in Medicine from Fudan University Medical College, Shanghai China, and a Ph.D. in Pharmacology from Medical College of Virginia, Richmond Virginia. Dr. Cao holds over 80 issued patents and applications for advanced cell therapies.
Guotong Xu

Guotong Xu,2014年11月起,担任该公司独立董事。他从2008年起,担任同济大学医学院的眼科与再生医学教授;以及是 Stem Cell Bank of TUSM的主任,该银行是中国干细胞研究和临床应用重要基地或中心。2008-2010年,在同济大学医学院担任副院长。在Alcon Lab和NEI/NIH作为博士后学习之后,被任命到北得克萨斯大学健康科学中心大学(University of North Texas Health Science Center)解剖学和细胞生物学系担任研究副教授。他于2007年在ISSCR合作举办了第一次大规模的国际干细胞研讨会。此后,他和他的同事发起成立中国干细胞生物学学会,并担任第一位会长。他还是国家干细胞与再生医学战略联盟(State Stem Cell & Regenerative Medicine Strategic Alliance)成立的活跃成员,以及担任委员会成员。他还是Chinese Journal of Cell and Stem Cell的副编辑。此外,他是中国为数不多的参与两个China National Major Projects 973计划的科学家之一Xu 持有North Texas Health Science Center的药理学博士学位,Peking Union Medical College和Chinese Academy of Medical Sciences的医学硕士学位,以及1982年从Harbin 医科大学获得的学士学位。


Guotong Xu has served as our director since February 2019. We have determined that Guotong Xu meets the criteria for independence set forth in Rule 10A-3 of the Exchange Act. Dr. Xu has been a professor of Ophthalmology and Pharmacology at Tongji University School of Medicine, or TUSM, since 2008 and a director of The East China Stem Cell Bank located inside TUSM, a center for stem cell research and clinical application in China. From March 2008 to July 2016 Dr. Xu served as dean of Tongji University School of Medicine. Dr. Xu has been an independent director of Guangzheng Group Co., Ltd., a company listed on the Shenzhen Stock Exchange Stock Code: 002524 and Zhejiang Shapuaisi Pharmaceutical Co., Ltd., a company listed on the Shanghai Stock Exchange (Stock Code: 603168), from June 2018 and August 2020 respectively. Prior to that, Dr. Xu served as an independent director of Cellular Biomedicine Group Inc. (Nasdaq: CBMG) from November 2014 to November 2016. Dr. Xu holds a Bachelor’s degree in Medicine from Harbin Medical University, an M.D. and a Master of Medical Sciences from Peking Union Medical College, Chinese Academy of Medical Sciences, and a Ph.D. in Pharmacology from University of North Texas Health Science Center, Fort Worth, Texas.
Guotong Xu,2014年11月起,担任该公司独立董事。他从2008年起,担任同济大学医学院的眼科与再生医学教授;以及是 Stem Cell Bank of TUSM的主任,该银行是中国干细胞研究和临床应用重要基地或中心。2008-2010年,在同济大学医学院担任副院长。在Alcon Lab和NEI/NIH作为博士后学习之后,被任命到北得克萨斯大学健康科学中心大学(University of North Texas Health Science Center)解剖学和细胞生物学系担任研究副教授。他于2007年在ISSCR合作举办了第一次大规模的国际干细胞研讨会。此后,他和他的同事发起成立中国干细胞生物学学会,并担任第一位会长。他还是国家干细胞与再生医学战略联盟(State Stem Cell & Regenerative Medicine Strategic Alliance)成立的活跃成员,以及担任委员会成员。他还是Chinese Journal of Cell and Stem Cell的副编辑。此外,他是中国为数不多的参与两个China National Major Projects 973计划的科学家之一Xu 持有North Texas Health Science Center的药理学博士学位,Peking Union Medical College和Chinese Academy of Medical Sciences的医学硕士学位,以及1982年从Harbin 医科大学获得的学士学位。
Guotong Xu has served as our director since February 2019. We have determined that Guotong Xu meets the criteria for independence set forth in Rule 10A-3 of the Exchange Act. Dr. Xu has been a professor of Ophthalmology and Pharmacology at Tongji University School of Medicine, or TUSM, since 2008 and a director of The East China Stem Cell Bank located inside TUSM, a center for stem cell research and clinical application in China. From March 2008 to July 2016 Dr. Xu served as dean of Tongji University School of Medicine. Dr. Xu has been an independent director of Guangzheng Group Co., Ltd., a company listed on the Shenzhen Stock Exchange Stock Code: 002524 and Zhejiang Shapuaisi Pharmaceutical Co., Ltd., a company listed on the Shanghai Stock Exchange (Stock Code: 603168), from June 2018 and August 2020 respectively. Prior to that, Dr. Xu served as an independent director of Cellular Biomedicine Group Inc. (Nasdaq: CBMG) from November 2014 to November 2016. Dr. Xu holds a Bachelor’s degree in Medicine from Harbin Medical University, an M.D. and a Master of Medical Sciences from Peking Union Medical College, Chinese Academy of Medical Sciences, and a Ph.D. in Pharmacology from University of North Texas Health Science Center, Fort Worth, Texas.
Wendy Hayes

Wendy Hayes于2018年12月开始担任我们的董事,Hayes女士自2018年9月起担任Roborock Inc.的首席财务官。此外,海斯女士目前担任独立TuanChe有限公司NASDAQ主任:TC和审计委员会主席。在加入Roborock前,海斯女士担任该检查从2013年5月上市公司会计监督委员会在美国的领导到九月2018从2009年1月至2013年4月海斯女士送达审计合伙人及高级经理德勤中国的北京和香港办事处。从2006年9月至2008年11月海斯女士担任以PMI Group公司海斯女士SEC和美国GAAP报告管理器还担任德勤在旧金山和毕马威会计师事务所在北京,香港等多个审计职位从1993年到2000年女士海耶斯获得了学士学位,在来自对外经济贸易大学国际金融学位,1991年从长江商学院在2012年海斯女士她的EMBA是美国加利福尼亚州和中国注册会计师。


Wendy Hayes has served as our director since January 7 2021. We have determined that Guotong Xu meets the criteria for independence set forth in Rule 10A-3 of the Exchange Act. Ms. Hayes has served as an independent director of Tuanche Limited Nasdaq: TC since November 2018 Burning Rock Biotech Limited (Nasdaq: BNR) since June 2020 and iHuman Inc. (NYSE: IH) since October 2020. Between May 2013 and September 2018 Ms. Hayes served as the Inspections Leader at the Public Company Accounting Oversight Board in the United States. Prior to that, Ms. Hayes was an audit partner at Deloitte (China). Ms. Hayes received her bachelor’s degree in International Finance from University of International Business and Economics in 1991 and her executive MBA from Cheung Kong Graduate School of Business in 2012. Ms. Hayes is a certified public accountant in the United States (California) and China.
Wendy Hayes于2018年12月开始担任我们的董事,Hayes女士自2018年9月起担任Roborock Inc.的首席财务官。此外,海斯女士目前担任独立TuanChe有限公司NASDAQ主任:TC和审计委员会主席。在加入Roborock前,海斯女士担任该检查从2013年5月上市公司会计监督委员会在美国的领导到九月2018从2009年1月至2013年4月海斯女士送达审计合伙人及高级经理德勤中国的北京和香港办事处。从2006年9月至2008年11月海斯女士担任以PMI Group公司海斯女士SEC和美国GAAP报告管理器还担任德勤在旧金山和毕马威会计师事务所在北京,香港等多个审计职位从1993年到2000年女士海耶斯获得了学士学位,在来自对外经济贸易大学国际金融学位,1991年从长江商学院在2012年海斯女士她的EMBA是美国加利福尼亚州和中国注册会计师。
Wendy Hayes has served as our director since January 7 2021. We have determined that Guotong Xu meets the criteria for independence set forth in Rule 10A-3 of the Exchange Act. Ms. Hayes has served as an independent director of Tuanche Limited Nasdaq: TC since November 2018 Burning Rock Biotech Limited (Nasdaq: BNR) since June 2020 and iHuman Inc. (NYSE: IH) since October 2020. Between May 2013 and September 2018 Ms. Hayes served as the Inspections Leader at the Public Company Accounting Oversight Board in the United States. Prior to that, Ms. Hayes was an audit partner at Deloitte (China). Ms. Hayes received her bachelor’s degree in International Finance from University of International Business and Economics in 1991 and her executive MBA from Cheung Kong Graduate School of Business in 2012. Ms. Hayes is a certified public accountant in the United States (California) and China.
David Guowei Wang

David Guowei Wang自2020年3月起担任我们董事。Wang博士在医疗保健行业有20多年的经验。Wang博士自2011年8月起担任OrbiMed Advisors LLC亚洲合伙人兼高级董事总经理。他自2016年4月起担任港交所上市公司AK Medical Holdings Limited董事,自2010年3月起担任深交所上市公司Edan Instruments,Inc.董事(股份代号:300206)。在此之前,Wang博士于2006年4月至2011年7月担任WI Harper Group的医疗保健投资董事总经理。Wang博士拥有北京大学医学院基础医学学士学位和医学博士学位,加州理工学院发育生物学博士学位。


David Guowei Wang has served as our director since March 2020. Dr. Wang has served as Partner and Senior Managing Director, Asia, of OrbiMed Advisors LLC, since August 2011. He has served as director of AK Medical Holdings Limited, a company listed on the Hong Kong Stock Exchange Stock Code: 1789 since April 2016 and as director of Edan Instruments, Inc., a company listed in the Shenzhen Stock Exchange (Stock Code: 300206) since March 2010. Prior to that, Dr. Wang served as Managing Director of Healthcare Investment of WI Harper Group from April 2006 to July 2011. Dr. Wang holds a Bachelor’s degree in basic medicine and an M.D. from Peking University School of Medicine, and a Ph.D. in Developmental Biology from California Institute of Technology.
David Guowei Wang自2020年3月起担任我们董事。Wang博士在医疗保健行业有20多年的经验。Wang博士自2011年8月起担任OrbiMed Advisors LLC亚洲合伙人兼高级董事总经理。他自2016年4月起担任港交所上市公司AK Medical Holdings Limited董事,自2010年3月起担任深交所上市公司Edan Instruments,Inc.董事(股份代号:300206)。在此之前,Wang博士于2006年4月至2011年7月担任WI Harper Group的医疗保健投资董事总经理。Wang博士拥有北京大学医学院基础医学学士学位和医学博士学位,加州理工学院发育生物学博士学位。
David Guowei Wang has served as our director since March 2020. Dr. Wang has served as Partner and Senior Managing Director, Asia, of OrbiMed Advisors LLC, since August 2011. He has served as director of AK Medical Holdings Limited, a company listed on the Hong Kong Stock Exchange Stock Code: 1789 since April 2016 and as director of Edan Instruments, Inc., a company listed in the Shenzhen Stock Exchange (Stock Code: 300206) since March 2010. Prior to that, Dr. Wang served as Managing Director of Healthcare Investment of WI Harper Group from April 2006 to July 2011. Dr. Wang holds a Bachelor’s degree in basic medicine and an M.D. from Peking University School of Medicine, and a Ph.D. in Developmental Biology from California Institute of Technology.
Lili Shen

Lili Shen自2020年10月起担任我司董事。Shen女士在医疗保健行业有超过15年的工作经验。Shen女士在晨兴风险投资公司担任董事总经理,主要从事生物技术投资。在2010年8月加入晨兴创投之前,她于2009年2月至2010年8月在CVI医药上海有限公司担任董事,负责其在中国的整体业务运营。2004年3月至2008年8月,她在上海新峰会生物制药有限公司担任经理,主要在中国从事临床前项目管理和IND备案。Shen女士拥有西安交通大学化学工程与技术学士学位和生物化学与分子生物学硕士学位,复旦大学硕士学位。


Lili Shen has served as our director since October 20 2020. Ms. Shen serves as the managing director at Morningside Ventures, primarily focuses on biotechnology investments. Prior to joining Morningside Ventures in August 2010 she served as a director at CVI Pharmaceuticals Shanghai Limited from February 2009 to August 2010 and was responsible for its overall business operation in China. From March 2004 to August 2008 she served as a manager at Shanghai Newsummit Biopharma Co., Ltd., primarily engaged in preclinical project management and IND filing in China. Ms. Shen holds a Bachelor’s degree in Chemical Engineering & Technology and a Master’s degree in Biochemistry and Molecular Biology from Xi’an Jiaotong University, and an M.B.A. from Fudan University.
Lili Shen自2020年10月起担任我司董事。Shen女士在医疗保健行业有超过15年的工作经验。Shen女士在晨兴风险投资公司担任董事总经理,主要从事生物技术投资。在2010年8月加入晨兴创投之前,她于2009年2月至2010年8月在CVI医药上海有限公司担任董事,负责其在中国的整体业务运营。2004年3月至2008年8月,她在上海新峰会生物制药有限公司担任经理,主要在中国从事临床前项目管理和IND备案。Shen女士拥有西安交通大学化学工程与技术学士学位和生物化学与分子生物学硕士学位,复旦大学硕士学位。
Lili Shen has served as our director since October 20 2020. Ms. Shen serves as the managing director at Morningside Ventures, primarily focuses on biotechnology investments. Prior to joining Morningside Ventures in August 2010 she served as a director at CVI Pharmaceuticals Shanghai Limited from February 2009 to August 2010 and was responsible for its overall business operation in China. From March 2004 to August 2008 she served as a manager at Shanghai Newsummit Biopharma Co., Ltd., primarily engaged in preclinical project management and IND filing in China. Ms. Shen holds a Bachelor’s degree in Chemical Engineering & Technology and a Master’s degree in Biochemistry and Molecular Biology from Xi’an Jiaotong University, and an M.B.A. from Fudan University.

高管简历

中英对照 |  中文 |  英文
曹伟

曹伟,曹先生自2013年2月起担任我们总裁兼首席运营官,直至2013年9月29日获委任为我们首席执行官。曹先生自2013年2月起担任我司董事会董事。在此之前,2010年8月至2013年2月,曹博士担任Cellular Biomedicine Group Ltd.(我们的前身公司)总裁、COO兼董事。2006年8月至2010年7月,曹博士担任基因分析行业公司Affymetrix中国公司总经理兼董事长。曹博士在科研、产品开发和创业方面拥有30多年的专业经验。曾任拜耳诊断亚太区(现西门子)技术经理、Genomultix有限公司总经理、无锡新区医院院长。曹博士在哈佛医学院和斯坦福大学医学中心的免疫药理学领域有丰富的研究经验。曹博士拥有复旦大学医学院医学学士学位,弗吉尼亚州里士满弗吉尼亚医学院药理学博士学位。他是基因分析和干细胞技术领域,特别是脂肪来源干细胞制备及其疾病治疗应用领域26项专利中命名的发明人。


Wei Cao has served as our Chairman of the Board and Chief Executive Officer since May 2017. Prior to founding our company, Dr. Cao co-founded Cellular Biomedicine Group, Inc. Nasdaq: CBMG, a Nasdaq-listed company engaging in developing proprietary cell therapies for the treatment of cancer and degenerative diseases, and served several positions at CBMG, such as chief operating officer, chief executive officer and director, from August 2010 to January 2016. Dr. Cao holds a Bachelor’s degree in Medicine from Fudan University Medical College, Shanghai China, and a Ph.D. in Pharmacology from Medical College of Virginia, Richmond Virginia. Dr. Cao holds over 80 issued patents and applications for advanced cell therapies.
曹伟,曹先生自2013年2月起担任我们总裁兼首席运营官,直至2013年9月29日获委任为我们首席执行官。曹先生自2013年2月起担任我司董事会董事。在此之前,2010年8月至2013年2月,曹博士担任Cellular Biomedicine Group Ltd.(我们的前身公司)总裁、COO兼董事。2006年8月至2010年7月,曹博士担任基因分析行业公司Affymetrix中国公司总经理兼董事长。曹博士在科研、产品开发和创业方面拥有30多年的专业经验。曾任拜耳诊断亚太区(现西门子)技术经理、Genomultix有限公司总经理、无锡新区医院院长。曹博士在哈佛医学院和斯坦福大学医学中心的免疫药理学领域有丰富的研究经验。曹博士拥有复旦大学医学院医学学士学位,弗吉尼亚州里士满弗吉尼亚医学院药理学博士学位。他是基因分析和干细胞技术领域,特别是脂肪来源干细胞制备及其疾病治疗应用领域26项专利中命名的发明人。
Wei Cao has served as our Chairman of the Board and Chief Executive Officer since May 2017. Prior to founding our company, Dr. Cao co-founded Cellular Biomedicine Group, Inc. Nasdaq: CBMG, a Nasdaq-listed company engaging in developing proprietary cell therapies for the treatment of cancer and degenerative diseases, and served several positions at CBMG, such as chief operating officer, chief executive officer and director, from August 2010 to January 2016. Dr. Cao holds a Bachelor’s degree in Medicine from Fudan University Medical College, Shanghai China, and a Ph.D. in Pharmacology from Medical College of Virginia, Richmond Virginia. Dr. Cao holds over 80 issued patents and applications for advanced cell therapies.
Martina Sersch

Martina Sersch自2020年起担任我们的首席医疗官。Sersch博士在多国公司和生物技术公司拥有超过25年的学术和行业经验以及在细胞和基因治疗、免疫肿瘤学、mAb和小分子方面的丰富经验。在加入我们之前,Sersch博士曾担任Mustang Bio公司,纳斯达克:MBIO, 一个纳斯达克上市的CAR-T、细胞和基因治疗公司的首席医疗官。2018年10月至2019年9月,她领导了基因和细胞疗法的临床开发,用于治疗罕见病和血液以及实体瘤适应症。她成功地完成了CAR-T细胞治疗急性髓系白血病、浆细胞样树突状细胞肿瘤和骨髓增生异常综合征的IND提交和批准。从2016年12月到2018年9月,Sersch博士担任Amgen Inc.的执行医疗总监,领导早期和晚期临床开发战略和方案,担任血液学主管。除其他外,她还负责成功地提出和批准了一种治疗多发性骨髓瘤的新的联合疗法,并领导了几项关键举措,包括评估不同族裔群体的安全调查结果和潜在差异。此外,她的职责还包括全球备案和区域发展战略等一揽子活动。在此之前,她于2011年至2016年担任罗氏/基因泰克公司(Roche/Genentech Inc.)的高级医疗总监,在实体肿瘤领域担任全球开发领导者,领导欧洲、亚洲和美国的全球和区域临床开发活动,其中包括在MCRC中成功开展单抗的全球备案活动。在Roche/Genentech公司任职期间,她以不同的跨职能身份开展工作,承担越来越多的责任,包括在亚太地区担任全球生物制剂战略负责人。在加入Genentech公司之前,Sersch博士在辉瑞公司工作多年,在国家、区域和全球范围内发挥作用,承担着越来越多的责任,包括开发早期免疫疗法药剂。Sersch博士拥有德国海德堡大学的医学博士和博士学位。


Martina Sersch has served as our Chief Medical Officer since 2020. Prior to joining us, Dr. Sersch served as chief medical officer of Mustang Bio, Inc. Nasdaq: MBIO, a Nasdaq-listed CAR-T, cell and gene therapy company, from October 2018 to September 2019 where she led the clinical development for gene and cellular therapies for the treatment of rare diseases and hematological as well as solid tumor indications. She accomplished the successful IND submission and approval of a CAR-T cell therapy in acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome. From December 2016 to September 2018 Dr. Sersch served as Executive Medical Director at Amgen Inc. leading early and late stage clinical development strategies and programs as hematology lead. Amongst other she was responsible for the successful filing and approval of a novel combination therapy in multiple myeloma and lead several key initiatives including the assessment of safety findings and potential differences in different ethnic groups. In addition, her responsibilities included portfolio activities such as global filings and regional development strategies. Prior to this role, she served as a Senior Medical Director at Roche/Genentech Inc from 2011 to 2016 where she served as Global Development Leader in solid tumors leading global and regional clinical development activities in Europe, Asia and the United States which included successful global filing activities for a mAb in mCRC. During her tenure at Roche/Genentech Inc, she worked in different cross functional capacities with increasing responsibilities including in the Asia-Pacific region as Global Biologics Strategy leader. Before joining Genentech Inc, Dr. Sersch worked many years at Pfizer Inc in country, regional and global roles with increasing responsibilities including the development of early immunotherapy agents. Dr. Sersch holds an M.D. and a doctorate degree from the University of Heidelberg in Germany.
Martina Sersch自2020年起担任我们的首席医疗官。Sersch博士在多国公司和生物技术公司拥有超过25年的学术和行业经验以及在细胞和基因治疗、免疫肿瘤学、mAb和小分子方面的丰富经验。在加入我们之前,Sersch博士曾担任Mustang Bio公司,纳斯达克:MBIO, 一个纳斯达克上市的CAR-T、细胞和基因治疗公司的首席医疗官。2018年10月至2019年9月,她领导了基因和细胞疗法的临床开发,用于治疗罕见病和血液以及实体瘤适应症。她成功地完成了CAR-T细胞治疗急性髓系白血病、浆细胞样树突状细胞肿瘤和骨髓增生异常综合征的IND提交和批准。从2016年12月到2018年9月,Sersch博士担任Amgen Inc.的执行医疗总监,领导早期和晚期临床开发战略和方案,担任血液学主管。除其他外,她还负责成功地提出和批准了一种治疗多发性骨髓瘤的新的联合疗法,并领导了几项关键举措,包括评估不同族裔群体的安全调查结果和潜在差异。此外,她的职责还包括全球备案和区域发展战略等一揽子活动。在此之前,她于2011年至2016年担任罗氏/基因泰克公司(Roche/Genentech Inc.)的高级医疗总监,在实体肿瘤领域担任全球开发领导者,领导欧洲、亚洲和美国的全球和区域临床开发活动,其中包括在MCRC中成功开展单抗的全球备案活动。在Roche/Genentech公司任职期间,她以不同的跨职能身份开展工作,承担越来越多的责任,包括在亚太地区担任全球生物制剂战略负责人。在加入Genentech公司之前,Sersch博士在辉瑞公司工作多年,在国家、区域和全球范围内发挥作用,承担着越来越多的责任,包括开发早期免疫疗法药剂。Sersch博士拥有德国海德堡大学的医学博士和博士学位。
Martina Sersch has served as our Chief Medical Officer since 2020. Prior to joining us, Dr. Sersch served as chief medical officer of Mustang Bio, Inc. Nasdaq: MBIO, a Nasdaq-listed CAR-T, cell and gene therapy company, from October 2018 to September 2019 where she led the clinical development for gene and cellular therapies for the treatment of rare diseases and hematological as well as solid tumor indications. She accomplished the successful IND submission and approval of a CAR-T cell therapy in acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome. From December 2016 to September 2018 Dr. Sersch served as Executive Medical Director at Amgen Inc. leading early and late stage clinical development strategies and programs as hematology lead. Amongst other she was responsible for the successful filing and approval of a novel combination therapy in multiple myeloma and lead several key initiatives including the assessment of safety findings and potential differences in different ethnic groups. In addition, her responsibilities included portfolio activities such as global filings and regional development strategies. Prior to this role, she served as a Senior Medical Director at Roche/Genentech Inc from 2011 to 2016 where she served as Global Development Leader in solid tumors leading global and regional clinical development activities in Europe, Asia and the United States which included successful global filing activities for a mAb in mCRC. During her tenure at Roche/Genentech Inc, she worked in different cross functional capacities with increasing responsibilities including in the Asia-Pacific region as Global Biologics Strategy leader. Before joining Genentech Inc, Dr. Sersch worked many years at Pfizer Inc in country, regional and global roles with increasing responsibilities including the development of early immunotherapy agents. Dr. Sersch holds an M.D. and a doctorate degree from the University of Heidelberg in Germany.
Yili Kevin Xie

Yili Kevin Xie自2020年7月起担任我们的首席财务官。Xie博士拥有超过18年的医疗投资经验。在加入我们公司之前,Xie博士于2015年3月至2020年7月在复星集团担任多个领导职务,包括担任复星医疗控股总裁及复星驻纽约首席代表。Xie博士自2019年10月起担任Viewray Inc.(NASDAQ:VRAY)董事,自2020年9月起担任Alpha Healthcare Acquisition Corp(NASDAQ:AHACU)董事。2012年2月至2015年3月,Xie博士担任投资公司Kinglington Capital的执行合伙人。他于2010年4月至2012年2月担任Locst Walk Capital的投资组合经理。2009年1月至2010年1月,Xie博士担任全球对冲基金Scopia Capital的医疗保健部门主管。从2005年到2008年,他担任医疗保健对冲基金Great Point Partners的首席执行官和董事总经理。Xie博士曾于2002年6月至2005年7月担任资产管理公司Delaware Investments的股票分析师。Xie博士拥有中国天津大学学士学位,纽约城市大学博士学位,宾夕法尼亚大学沃顿商学院硕士学位。


Yili Kevin Xie has served as our Chief Financial Officer since July 2020. Prior to joining our company, Dr. Xie served in various leadership positions in Fosun Group from March 2015 to July 2020 including as the President of Fosun Healthcare Holdings and Chief Representative of Fosun, New York. Dr. Xie has served as director of ViewRay Inc Nasdaq: VRAY since October 2019 and director of Alpha Healthcare Acquisition Corp (Nasdaq: AHACU) since September 2020. From February 2012 to March 2015 Dr. Xie served as Managing Partner for Kinglington Capital, an investment company. He co-founded and served as Portfolio Manager for Locust Walk Capital from April 2010 to February 2012. From January 2009 to January 2010 Dr. Xie served as Healthcare Sector Head for Scopia Capital, a global hedge fund. From 2005 to 2008 he served as Principal and subsequently Managing Director for Great Point Partners, a healthcare hedge fund. Dr. Xie served as an Equity Analyst for Delaware Investments, an asset management firm, from June 2002 to July 2005. Dr. Xie holds a Bachelor’s degree from Tianjin University in China, a Ph.D. in Chemistry from The City University in New York, and an M.B.A. from The Wharton School, University of Pennsylvania.
Yili Kevin Xie自2020年7月起担任我们的首席财务官。Xie博士拥有超过18年的医疗投资经验。在加入我们公司之前,Xie博士于2015年3月至2020年7月在复星集团担任多个领导职务,包括担任复星医疗控股总裁及复星驻纽约首席代表。Xie博士自2019年10月起担任Viewray Inc.(NASDAQ:VRAY)董事,自2020年9月起担任Alpha Healthcare Acquisition Corp(NASDAQ:AHACU)董事。2012年2月至2015年3月,Xie博士担任投资公司Kinglington Capital的执行合伙人。他于2010年4月至2012年2月担任Locst Walk Capital的投资组合经理。2009年1月至2010年1月,Xie博士担任全球对冲基金Scopia Capital的医疗保健部门主管。从2005年到2008年,他担任医疗保健对冲基金Great Point Partners的首席执行官和董事总经理。Xie博士曾于2002年6月至2005年7月担任资产管理公司Delaware Investments的股票分析师。Xie博士拥有中国天津大学学士学位,纽约城市大学博士学位,宾夕法尼亚大学沃顿商学院硕士学位。
Yili Kevin Xie has served as our Chief Financial Officer since July 2020. Prior to joining our company, Dr. Xie served in various leadership positions in Fosun Group from March 2015 to July 2020 including as the President of Fosun Healthcare Holdings and Chief Representative of Fosun, New York. Dr. Xie has served as director of ViewRay Inc Nasdaq: VRAY since October 2019 and director of Alpha Healthcare Acquisition Corp (Nasdaq: AHACU) since September 2020. From February 2012 to March 2015 Dr. Xie served as Managing Partner for Kinglington Capital, an investment company. He co-founded and served as Portfolio Manager for Locust Walk Capital from April 2010 to February 2012. From January 2009 to January 2010 Dr. Xie served as Healthcare Sector Head for Scopia Capital, a global hedge fund. From 2005 to 2008 he served as Principal and subsequently Managing Director for Great Point Partners, a healthcare hedge fund. Dr. Xie served as an Equity Analyst for Delaware Investments, an asset management firm, from June 2002 to July 2005. Dr. Xie holds a Bachelor’s degree from Tianjin University in China, a Ph.D. in Chemistry from The City University in New York, and an M.B.A. from The Wharton School, University of Pennsylvania.